Vandetanib and lenvatinib are used in the treatment of thyroid cancer,163,164 NSCLC,165 and hepatocellular carcinoma166 due to their ability to inhibit angiogenesis by binding to targets such as FGFR, VEGFR, and RET. Here, KDR is linked to thyroid cancer.